PDSB - PDS Biotech under pressure after pricing equity offering at $8.50

PDS Biotechnology (PDSB) slumps 27% premarket after pricing its public offering of 5,294,118 common shares at $8.50/share, for expected gross proceeds of ~$45M.Underwriters' over-allotment is an additional 794,117 shares. Net proceeds will be used for the development of clinical pipeline and for general corporate purposes including working capital.Closing date is June 17.Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.Previously (June 14): PDS Biotech under pressure on proposing stock offering

For further details see:

PDS Biotech under pressure after pricing equity offering at $8.50